SQZ Biotech
- Founded: 2013
- Location: Watertown, MA
- Employee range: 50 - 200
- Clinical stage: Clin1/Clin2 (fast track)
- Therapy area: Multiple cancers (partner: Roche)
- Drug types: ONC
- Lead product: SQZ eAPCs
- Product link: https://sqzbiotech.com/therapeutic-platforms/pipeline/
- Funding: $60M stock Feb 2021; $81M IPO Oct 2020; $65M D May 2020; $72M Aug 2018; $16M B Oct 2016; $5M A Jun 2015
sqzbiotech.com linkedin.com job board
Short description:
Cell therapies for multiple indications using their proprietary CellSqueeze platform
Drug notes:
SQZ AACs Clin1/Clin2 multiple cancers
Long description:
SQZ Biotechnologies focuses on cell therapies to treat patients with cancer, autoimmune and infectious diseases. To identify treatments, SQZ is using their Cell Squeeze technology. This involves physically squeezing cells at high speeds, temporarily opening gaps in the cell membrane to enable potential biologics to enter before the membrane reseals. Cell Squeeze has worked with all cell types tested so far, but SQZ is prioritizing three platforms for immune cells to alter their response to disease-specific antigens. SQZ’s approach does not depend on genetic alterations, thus reducing unintended perturbations and enabling rapid, scalable and economic production of cell therapies. SQZ has created a diverse pipeline spanning multiple indications that are in Phase 1/2 clinical trials.
Jobs:
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com